AJP - Regu Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 294: R411-R420, 2008. First published November 21, 2007; doi:10.1152/ajpregu.00465.2007
0363-6119/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/2/R411    most recent
00465.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Fraga, D.
Right arrow Articles by Zampronio, A. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fraga, D.
Right arrow Articles by Zampronio, A. R.

INFLAMMATION AND CYTOKINES

Endogenous opioids: role in prostaglandin-dependent and -independent fever

Daniel Fraga,1,2 Renes R. Machado,2 Luíz C. Fernandes,3 Glória E. P. Souza,2 and Aleksander R. Zampronio1

1Department of Pharmacology and 3Department of Physiology, Biological Sciences Section, Federal University of Paraná, Curitiba, Paraná, Brazil; and 2Laboratory of Pharmacology, Faculty of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

Submitted 29 June 2007 ; accepted in final form 13 November 2007

This study evaluated the participation of µ-opioid-receptor activation in body temperature (Tb) during normal and febrile conditions (including activation of heat conservation mechanisms) and in different pathways of LPS-induced fever. The intracerebroventricular treatment of male Wistar rats with the selective opioid µ-receptor-antagonist cyclic D-Phe-Cys-Try-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP; 0.1–1.0 µg) reduced fever induced by LPS (5.0 µg/kg) but did not change Tb at ambient temperatures of either 20°C or 28°C. The subcutaneous, intracerebroventricular, and intrahypothalamic injection of morphine (1.0–10.0 mg/kg, 3.0–30.0 µg, and 1–100 ng, respectively) produced a dose-dependent increase in Tb. Intracerebroventricular morphine also produced a peripheral vasoconstriction. Both effects were abolished by CTAP. CTAP (1.0 µg icv) reduced the fever induced by intracerebroventricular administration of TNF-{alpha} (250 ng), IL-6 (300 ng), CRF (2.5 µg), endothelin-1 (1.0 pmol), and macrophage inflammatory protein (500 pg) and the first phase of the fever induced by PGF2{alpha} (500.0 ng) but not the fever induced by IL-1β (3.12 ng) or PGE2 (125.0 ng) or the second phase of the fever induced by PGF2{alpha}. Morphine-induced fever was not modified by the cyclooxygenase (COX) inhibitor indomethacin (2.0 mg/kg). In addition, morphine injection did not induce the expression of COX-2 in the hypothalamus, and CTAP did not modify PGE2 levels in cerebrospinal fluid or COX-2 expression in the hypothalamus after LPS injection. In conclusion, our results suggest that LPS and endogenous pyrogens (except IL-1β and prostaglandins) recruit the opioid system to cause a µ-receptor-mediated fever.

prostaglandin independent; body temperature; morphine; CTAP



Address for reprint requests and other correspondence: A. R. Zampronio, Departamento de Farmacologia, Setor de Ciências Biológicas, Universidade Federal do Paraná; Caixa Postal 19031, CEP 81540-970, Curitiba, Paraná, Brazil (e-mail: aleksander{at}ufpr.br)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.